Literature DB >> 26468612

The initial neurosurgical interventions for the treatment of posthaemorrhagic hydrocephalus in preterm infants: A focused review.

Malik Zaben1,2, Amy Finnigan1, Muhammed I Bhatti2, Paul Leach2.   

Abstract

BACKGROUND: Post-haemorrhagic hydrocephalus (PHH), a potential consequence of grade II-IV germinal matrix haemorrhage, remains a significant problem in premature infants with long-term neurodevelopmental disabilities and high mortality rates. Early ventriculoperitoneal shunt (VPS) insertion is associated with a high failure rate and many complications; hence, temporising measures are always instituted until the infant is mature (age and/or weight) enough.
METHODS: We have reviewed the recently available literature on the usefulness and complications of the initial measures used in the treatment of PHH; particularly, focusing on serial cerebrospinal fluid (CSF) tapping, external ventricular drainage (EVD), ventriculosubgaleal shunts (VSG), ventricular access devices (VADs), endoscopic third ventriculostomy (ETV) with and without coagulation of the choroid plexus.
RESULTS: Randomised controlled trials (RCTs) have failed to demonstrate a significant effect of serial lumbar punctures on the rates of morbidity, mortality or conversion to permanent VPS in the treatment of PHH. Retrospective studies, mostly with small patients' numbers, provide not only a considerable controversy regarding EVD, VSG, VADs and ETV usefulness in the management of PHH but also variable rates on their complications. None of these variables have, however, been tested using RCTs.
CONCLUSION: There is no level-one evidence to support the superiority of any of the currently available temporising measures in the initial treatment of PHH over others. The need for such rigorous studies remains largely unmet. We feel that a UK multi-centre-RCT is paramount to provide neurosurgeons with the evidence needed to choose the best initial approach for PPH treatment, yet with minimal complications' rate.

Entities:  

Keywords:  cerebrospinal fluid drainage; hydrocephalus; intraventricular haemorrhage; ventriculoperitoneal shunt

Mesh:

Year:  2015        PMID: 26468612     DOI: 10.3109/02688697.2015.1096911

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  6 in total

1.  Does ventricle size contribute to cognitive outcomes in posthemorrhagic hydrocephalus? Role of early definitive intervention.

Authors:  Mounica Paturu; Regina L Triplett; Siddhant Thukral; Dimitrios Alexopoulos; Christopher D Smyser; David D Limbrick; Jennifer M Strahle
Journal:  J Neurosurg Pediatr       Date:  2021-10-15       Impact factor: 2.713

Review 2.  New concept of the pathogenesis and therapeutic orientation of acquired communicating hydrocephalus.

Authors:  Hao Xu
Journal:  Neurol Sci       Date:  2016-04-26       Impact factor: 3.307

Review 3.  A neonatal neuroNICU collaborative approach to neuromonitoring of posthemorrhagic ventricular dilation in preterm infants.

Authors:  Brett A Whittemore; Dale M Swift; Jennifer M Thomas; Lina F Chalak
Journal:  Pediatr Res       Date:  2021-02-24       Impact factor: 3.756

4.  Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery.

Authors:  Cheng Lu; Yuyi Zhang; Mingyu Chen; Ping Zhong; Yuancheng Chen; Jicheng Yu; Xiaojie Wu; Jufang Wu; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Quantitative 3-D head ultrasound measurements of ventricle volume to determine thresholds for preterm neonates requiring interventional therapies following posthemorrhagic ventricle dilatation.

Authors:  Jessica Kishimoto; Aaron Fenster; David S C Lee; Sandrine de Ribaupierre
Journal:  J Med Imaging (Bellingham)       Date:  2018-06-26

Review 6.  Surgical management of intraventricular hemorrhage and posthemorrhagic hydrocephalus in premature infants.

Authors:  Meng-Fai Kuo
Journal:  Biomed J       Date:  2020-04-21       Impact factor: 4.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.